Shares of Revance Therapeutics Inc (NASDAQ:RVNC) have received an average recommendation of “Buy” from the fourteen analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $47.00.

Several analysts have issued reports on RVNC shares. Cantor Fitzgerald set a $50.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. JMP Securities downgraded shares of Revance Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, September 17th. BidaskClub downgraded shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 15th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Revance Therapeutics in a report on Monday, September 17th.

Shares of NASDAQ RVNC opened at $23.46 on Wednesday. Revance Therapeutics has a 12-month low of $21.45 and a 12-month high of $37.45.

Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.04. Revance Therapeutics had a negative net margin of 4,205.52% and a negative return on equity of 61.45%. The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $0.49 million. As a group, sell-side analysts forecast that Revance Therapeutics will post -3.83 EPS for the current year.

In related news, insider Cyril Allouche sold 2,188 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $23.72, for a total transaction of $51,899.36. Following the transaction, the insider now owns 6,938 shares of the company’s stock, valued at $164,569.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 18.86% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its stake in shares of Revance Therapeutics by 9.0% during the third quarter. BlackRock Inc. now owns 3,194,983 shares of the biopharmaceutical company’s stock valued at $79,395,000 after buying an additional 263,003 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Revance Therapeutics by 26.7% during the third quarter. Bank of New York Mellon Corp now owns 2,464,617 shares of the biopharmaceutical company’s stock valued at $61,245,000 after buying an additional 519,938 shares during the period. Alliancebernstein L.P. lifted its stake in shares of Revance Therapeutics by 26.1% during the third quarter. Alliancebernstein L.P. now owns 1,651,949 shares of the biopharmaceutical company’s stock valued at $41,051,000 after buying an additional 341,896 shares during the period. Fosun International Ltd lifted its stake in shares of Revance Therapeutics by 48.0% during the second quarter. Fosun International Ltd now owns 472,532 shares of the biopharmaceutical company’s stock valued at $12,971,000 after buying an additional 153,219 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Revance Therapeutics by 22.5% during the second quarter. Northern Trust Corp now owns 415,856 shares of the biopharmaceutical company’s stock valued at $11,415,000 after buying an additional 76,406 shares during the period. 94.42% of the stock is currently owned by institutional investors and hedge funds.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Recommended Story: What does RSI mean?

Analyst Recommendations for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.